Therapeutics News and Research

RSS

Researchers infuse antibody-studded iron nanoparticles into bloodstream to treat heart attack damage

Researchers at the Cedars-Sinai Heart Institute infused antibody-studded iron nanoparticles into the bloodstream to treat heart attack damage.

10 Sep 2014

Researchers identify non-protein-coding RNA whose expression linked to ovarian cancer

Over the years researchers have made tremendous strides in the understanding and treatment of cancer by searching genomes for links between genetic alterations and disease.

10 Sep 2014

Scientists identify how immune cells use two critical receptors to clear dead cells from the body

In most of the tissues of the body, specialized immune cells are entrusted with the task of engulfing the billions of dead cells that are generated every day.

8 Sep 2014

Combination miRNA therapy offers promising therapeutic avenue for non-small-cell lung cancer

Micro RNAs (miRNA) have recently emerged as key therapeutic agents against cancers and are actively being evaluated in pre-clinical models of various cancers as well as in human clinical trials.

8 Sep 2014

Researchers investigating new ways to identify drugs against Ebola virus infection

Researchers from the University of Liverpool in collaboration with Public Health England have been investigating new ways to identify drugs that could be used to treat Ebola virus infection.

5 Sep 2014

FDA provides QIDP designation to Debiopharm’s Debio 1450 for treatment of ABSSSI

Debiopharm Group™(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including anti-infective and oncology therapeutics as well as companion diagnostics, today announced that the US Food and Drug Administration (FDA) has designated its anti-infectious agent Debio 1450 as a Qualified Infectious Disease Product (QIDP) for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

4 Sep 2014

Novira completes Phase 1a clinical study of NVR-1221 for treatment of HBV infection

Novira Therapeutics, Inc., a privately held biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection, today announced successful completion of a Phase 1a clinical study of NVR-1221.

4 Sep 2014

Treating wet AMD with gold nanoparticles: an interview with Jim Taylor, CEO, Oraya Therapeutics

Wet AMD is characterized by abnormal growth of blood vessels in the macula (the area of the eye containing vision-enabling photoreceptors), and is responsible for the vast majority of severe vision loss in the industrialized world.

4 Sep 2014

New way to reduce abnormal blood vessel growth and leakage in eye

Working with mice, a multicenter team of researchers has found a new way to reduce the abnormal blood vessel growth and leakage in the eye that accompany some eye diseases. The finding could lead to the development of new drugs for wet macular degeneration and diabetic macular edema.

4 Sep 2014

New regulatory component in infectious bacterium helps explain ability to survive in human body

The discovery of a new regulatory component in an infectious bacterium could aid efforts to explain its ability to survive in the human body, report microbiologists at The University of Texas Health Science Center at Houston (UTHealth) and University of Maryland, College Park, in the journal Science.

3 Sep 2014

State highlights: Mass. health care costs grow smaller 2.3 percent; new rules in Calif. for inmates with mental illness

Two years ago, Massachusetts set what was considered an ambitious goal: The state would not let that persistent monster, rising health care costs, increase faster than the economy as a whole.

3 Sep 2014

Clinical studies to treat unmet medical need post-transplantation

A class of biotechnology drugs called monoclonal antibodies is now being tested in clinical studies to treat an unmet medical need post-transplantation, called delayed graft function

3 Sep 2014

New approach to turn diseased cells into unique manufacturing sites for treating muscular dystrophy

In a new study that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have adapted a chemical approach to turn diseased cells into unique manufacturing sites for molecules that can treat a form of muscular dystrophy.

3 Sep 2014

ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

Antisense Therapeutics Limited is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly.

2 Sep 2014

Soligenix announces promising preliminary results from study on ricin toxin vaccine

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today promising preliminary results from a preclinical study with its ricin toxin vaccine RiVax™, in a non-human primate (NHP) lethal aerosol exposure model.

2 Sep 2014

Digoxin drug increases risk of adverse cardiovascular events or sudden death

Digoxin may increase the risk of death in patients with atrial fibrillation (AF) by approximately 20%, according to results from the ROCKET AF trial presented at ESC Congress today by Dr Manesh Patel, director of interventional cardiology and catheterisation labs at Duke University Health System in Durham, North Carolina, US.

2 Sep 2014

Scientists develop synthetic amino acid that can impact 3D structure of bioactive peptides

One of the greatest challenges in modern medicine is developing drugs that are highly effective against a target, but with minimal toxicity and side-effects to the patient. Such properties are directly related to the 3D structure of the drug molecule.

1 Sep 2014

Pfenex reports total revenue of $3.3 million for second quarter 2014

Pfenex Inc., a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture proteins including biosimilar therapeutics, today provided a business update and reported financial results for the second quarter ended June 30, 2014.

30 Aug 2014

iCo Therapeutics reports financial results for second quarter 2014

iCo Therapeutics, today reported financial results for the six months ended June 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").

29 Aug 2014

New online analytic tool enhances process of re-engineering cells for biomedical research

A Mayo Clinic researcher and his collaborators have developed an online analytic tool that will speed up and enhance the process of re-engineering cells for biomedical investigation. CellNet is a free-use Internet platform that uses network biology methods to aid stem cell engineering.

29 Aug 2014

Therapeutics News and Research

Researchers infuse antibody-studded iron nanoparticles into bloodstream to treat heart attack damage

Researchers identify non-protein-coding RNA whose expression linked to ovarian cancer

Scientists identify how immune cells use two critical receptors to clear dead cells from the body

Combination miRNA therapy offers promising therapeutic avenue for non-small-cell lung cancer

Researchers investigating new ways to identify drugs against Ebola virus infection

FDA provides QIDP designation to Debiopharm’s Debio 1450 for treatment of ABSSSI

Novira completes Phase 1a clinical study of NVR-1221 for treatment of HBV infection

Treating wet AMD with gold nanoparticles: an interview with Jim Taylor, CEO, Oraya Therapeutics

New way to reduce abnormal blood vessel growth and leakage in eye

New regulatory component in infectious bacterium helps explain ability to survive in human body

State highlights: Mass. health care costs grow smaller 2.3 percent; new rules in Calif. for inmates with mental illness

Clinical studies to treat unmet medical need post-transplantation

New approach to turn diseased cells into unique manufacturing sites for treating muscular dystrophy

ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

Soligenix announces promising preliminary results from study on ricin toxin vaccine

Digoxin drug increases risk of adverse cardiovascular events or sudden death

Scientists develop synthetic amino acid that can impact 3D structure of bioactive peptides

Pfenex reports total revenue of $3.3 million for second quarter 2014

iCo Therapeutics reports financial results for second quarter 2014

New online analytic tool enhances process of re-engineering cells for biomedical research

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News